Literature DB >> 17014002

Predictors of carotid atherosclerosis in systemic lupus erythematosus.

Kathleen Maksimowicz-McKinnon1, Laurence S Magder, Michelle Petri.   

Abstract

OBJECTIVE: Patients with systemic lupus erythematosus (SLE) are at increased risk for cardiovascular and cerebrovascular events, even after adjustment for traditional risk factors. We examined the association of traditional risk factors, novel markers of cardiovascular disease (C-reactive protein, homocysteine, lipoprotein(a), plasminogen activator inhibitor-1, fibrinogen), and markers indicative of SLE activity (including C3, C4, anti-dsDNA, and prednisone use) with the presence of significant plaque on carotid duplex imaging.
METHODS: Six hundred five patients with SLE enrolled in the Hopkins Lupus Cohort Study (92% female, 38% African-American) underwent carotid duplex testing. Prospectively gathered clinical, laboratory, and serologic data from their quarterly followup visits in the Hopkins Lupus Cohort were used in the analyses. For predictors that varied over time, such as cholesterol, the mean values during cohort participation were calculated for the analysis. Informed consent was obtained from all patients.
RESULTS: The presence of carotid plaque was strongly associated with age, ranging from 1% among those less than 30 years of age to 61% among those 60 years or older. After adjusting for age, there were moderate or strong associations of carotid plaque with male gender (age-adjusted risk 25% vs 13%; p = 0.051), hypertension (age-adjusted risk 18% vs 8%; p = 0.0001), diabetes mellitus (age-adjusted risk 19% vs 13%; p = 0.075), C3 > 120 mg/dl (age-adjusted risk 18% vs 11% and 14% for normal and low C3, respectively; p = 0.046), serum creatinine > 1.3 (age-adjusted risk 32% vs 13%; p = 0.039), and mean systolic blood pressure > 140 (age-adjusted risk 23% vs 13%; p = 0.028). There was no strong evidence of an association between plaque and SLE disease activity (age-adjusted risk 14% among those with adjusted mean SLEDAI > 3 vs 14% among those with lower SLEDAI) or with time since SLE diagnosis (age-adjusted risk 12%, 14%, and 16% among those with SLE for < 2, 2-8, and > 8 years, respectively; p = 0.49).
CONCLUSION: Traditional cardiovascular risk factors were associated with carotid plaque in SLE. However, SLE disease activity and duration of SLE are not strongly associated with carotid plaque. A "lupus factor" separate from traditional risk factors remains unidentified.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17014002

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  20 in total

1.  Association between depression and vascular disease in systemic lupus erythematosus.

Authors:  Carol M Greco; Tracy Li; Abdus Sattar; Amy H Kao; Natalya Danchenko; Daniel Edmundowicz; Kim Sutton-Tyrrell; Russell P Tracy; Lewis H Kuller; Susan Manzi
Journal:  J Rheumatol       Date:  2011-12-15       Impact factor: 4.666

Review 2.  The role of preventive cardiology in systemic lupus erythematosus.

Authors:  Jennifer Rae Elliott; Susan Manzi; Daniel Edmundowicz
Journal:  Curr Rheumatol Rep       Date:  2007-05       Impact factor: 4.592

3.  Nephritis and the risk of acute myocardial infarction in patients with systemic lupus erythematosus.

Authors:  D K Wells; M M Ward
Journal:  Clin Exp Rheumatol       Date:  2010-05-13       Impact factor: 4.473

4.  Use of atorvastatin in systemic lupus erythematosus in children and adolescents.

Authors:  L E Schanberg; C Sandborg; H X Barnhart; S P Ardoin; E Yow; G W Evans; K L Mieszkalski; N T Ilowite; A Eberhard; L F Imundo; Y Kimura; E von Scheven; E Silverman; S L Bowyer; M Punaro; N G Singer; D D Sherry; D McCurdy; M Klein-Gitelman; C Wallace; R Silver; L Wagner-Weiner; G C Higgins; H I Brunner; L Jung; J B Soep; A M Reed; J Provenzale; S D Thompson
Journal:  Arthritis Rheum       Date:  2012-01

5.  Mycophenolate mofetil (MMF) does not slow the progression of subclinical atherosclerosis in SLE over 2 years.

Authors:  Adnan N Kiani; Laurence S Magder; Michelle Petri
Journal:  Rheumatol Int       Date:  2011-07-27       Impact factor: 2.631

6.  Predictors of progression in atherosclerosis over 2 years in systemic lupus erythematosus.

Authors:  Adnan N Kiani; Wendy S Post; Laurence S Magder; Michelle Petri
Journal:  Rheumatology (Oxford)       Date:  2011-08-28       Impact factor: 7.580

7.  Association between depression and coronary artery calcification in women with systemic lupus erythematosus.

Authors:  Carol M Greco; Amy H Kao; Abdus Sattar; Natalya Danchenko; Kathleen M Maksimowicz-McKinnon; Daniel Edmundowicz; Kim Sutton-Tyrrell; Russell P Tracy; Lewis H Kuller; Susan Manzi
Journal:  Rheumatology (Oxford)       Date:  2009-03-13       Impact factor: 7.580

8.  Alpha-chlorofatty Acid and coronary artery or aorta calcium scores in women with systemic lupus erythematosus. A pilot study.

Authors:  Mary A Mahieu; Camelia P Guild; Carolyn J Albert; George T Kondos; James J Carr; Daniel Edmundowicz; David A Ford; Rosalind Ramsey-Goldman
Journal:  J Rheumatol       Date:  2014-08-01       Impact factor: 4.666

9.  The relationship between race, cigarette smoking and carotid intimal medial thickness in systemic lupus erythematosus.

Authors:  L V Scalzi; S Bhatt; R C Gilkeson; M L Shaffer
Journal:  Lupus       Date:  2009-10-27       Impact factor: 2.911

10.  Differences in subclinical cardiovascular disease between African American and Caucasian women with systemic lupus erythematosus.

Authors:  Elisa Y Rhew; Susan M Manzi; Alan R Dyer; Amy H Kao; Natalya Danchenko; Emma Barinas-Mitchell; Kim Sutton-Tyrrell; David D McPherson; William Pearce; Daniel Edmundowicz; George T Kondos; Rosalind Ramsey-Goldman
Journal:  Transl Res       Date:  2008-12-09       Impact factor: 7.012

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.